Your browser doesn't support javascript.
loading
RESISTANCE CONFERRING MUTATIONS IN SARS-CoV-2 DELTA FOLLOWING SOTROVIMAB INFUSION
Rebecca J Rockett; Kerri Basile; Susan Maddocks; Winkie Fong; Jessica E Agius; Jessica Johnson-Mackinnon; Alicia Arnott; Shona Chandra; Mailie Gall; Jenny L Draper; Elena Martinez; Eby M Sim; Clement Lee; Christine Ngo; Marc Ramsperger; Andrew N Ginn; Qinning Wang; Michael Fennell; Danny Ko; Ling Lim; Nicky Gilroy; Matthew VN Sullivan; Sharon C-A Chen; Jen Kok; Dominic E Dwyer; Vitali L Sintchenko.
Afiliación
  • Rebecca J Rockett; Sydney Institute of Infectious Diseases, University of Sydney, Sydney, New South Wales, Australia
  • Kerri Basile; Centre for Infectious Diseases and Microbiology Laboratory Services, New South Wales Health Pathology, Institute for Clinical Pathology and Medical Research, We
  • Susan Maddocks; Centre for Infectious Diseases and Microbiology Laboratory Services, New South Wales Health Pathology, Institute for Clinical Pathology and Medical Research, We
  • Winkie Fong; Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, Westmead, New South Wales, Australia
  • Jessica E Agius; Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, Westmead, New South Wales, Australia
  • Jessica Johnson-Mackinnon; Sydney Institute of Infectious Diseases, University of Sydney, Sydney, New South Wales, Australia
  • Alicia Arnott; Centre for Infectious Diseases and Microbiology Laboratory Services, New South Wales Health Pathology, Institute for Clinical Pathology and Medical Research, We
  • Shona Chandra; Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, Westmead, New South Wales, Australia
  • Mailie Gall; Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, Westmead, New South Wales, Australia
  • Jenny L Draper; Centre for Infectious Diseases and Microbiology Laboratory Services, New South Wales Health Pathology, Institute for Clinical Pathology and Medical Research, We
  • Elena Martinez; Centre for Infectious Diseases and Microbiology Laboratory Services, New South Wales Health Pathology, Institute for Clinical Pathology and Medical Research, We
  • Eby M Sim; Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, Westmead, New South Wales, Australia
  • Clement Lee; Centre for Infectious Diseases and Microbiology Laboratory Services, New South Wales Health Pathology, Institute for Clinical Pathology and Medical Research, We
  • Christine Ngo; Centre for Infectious Diseases and Microbiology Laboratory Services, New South Wales Health Pathology, Institute for Clinical Pathology and Medical Research, We
  • Marc Ramsperger; Centre for Infectious Diseases and Microbiology Laboratory Services, New South Wales Health Pathology, Institute for Clinical Pathology and Medical Research, We
  • Andrew N Ginn; Centre for Infectious Diseases and Microbiology Laboratory Services, New South Wales Health Pathology, Institute for Clinical Pathology and Medical Research, We
  • Qinning Wang; Centre for Infectious Diseases and Microbiology Laboratory Services, New South Wales Health Pathology, Institute for Clinical Pathology and Medical Research, We
  • Michael Fennell; Centre for Infectious Diseases and Microbiology Laboratory Services, New South Wales Health Pathology, Institute for Clinical Pathology and Medical Research, We
  • Danny Ko; Centre for Infectious Diseases and Microbiology Laboratory Services, New South Wales Health Pathology, Institute for Clinical Pathology and Medical Research, We
  • Ling Lim; Parramatta Public Health Unit, Western Sydney Local Health District, Parramatta, New South Wales, Australia
  • Nicky Gilroy; Department of Infectious Diseases, Westmead Hospital, Western Sydney Local Health District, Sydney, New South Wales, Australia
  • Matthew VN Sullivan; Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, Westmead, New South Wales, Australia
  • Sharon C-A Chen; Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, Westmead, New South Wales, Australia
  • Jen Kok; Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, Westmead, New South Wales, Australia
  • Dominic E Dwyer; Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, Westmead, New South Wales, Australia
  • Vitali L Sintchenko; Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, Westmead, New South Wales, Australia
Preprint en Inglés | medRxiv | ID: ppmedrxiv-21267628
ABSTRACT
Several Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) neutralising monoclonal antibodies (mAbs) have received emergency use authorisation by regulatory agencies for treatment and prevention of Coronavirus Disease 2019 (COVID-19), including in patients at risk for progression to severe disease. Here we report the persistence of viable SARS-CoV-2 in patients treated with sotrovimab and the rapid development of spike gene mutations that have been shown to confer high level resistance to sotrovimab in vitro. We highlight the need for SARS-CoV-2 genomic surveillance in at risk individuals to inform stewardship of mAbs use and prevent potential treatment failures.
Licencia
cc_by_nc_nd
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: Disponible Colección: Preprints Base de datos: medRxiv Tipo de estudio: Estudio pronóstico Idioma: Inglés Año: 2021 Tipo del documento: Preprint
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: Disponible Colección: Preprints Base de datos: medRxiv Tipo de estudio: Estudio pronóstico Idioma: Inglés Año: 2021 Tipo del documento: Preprint